Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized trial of olorofim vs AmBisome followed by standard of care for invasive aspergillosis
jRCT2031230313Phase 3Active, not recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Dec 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, single-blind trial of olorofim in invasive aspergillosis (IA) and aspergillosis (2 arms), sponsored by Shionogi & Co., Ltd. Primary endpoint: All-cause mortality at Day 42 (ITT population). Started Dec 2023; status: active, not recruiting.
02
Drugs
olorofim
03
Conditions
invasive aspergillosis (IA)aspergillosis
Beyond the preview
Go deeper on jRCT2031230313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230313.